1906 Drops are a commercial line of swallowable, fast-acting oral tablets (“pills”) formulated with microdoses of cannabis-derived cannabinoids combined with targeted botanical extracts and adaptogens. The brand name references the Pure Food and Drug Act of 1906, which marked the transition into modern federal drug regulation.
Product Identification & Formulations
1906 pills are small, film-coated, color-coded tablets designed to be swallowed with water (not chewed). Unlike standard pharmaceutical medications, these are regulated as adult-use/medical cannabis or hemp-derived dietary products depending on jurisdiction.
Formula – Primary Intended Effect – Cannabinoid Profile (Per Drop) – Key Botanical / Functional Ingredients
- Genius – Cognitive focus & mental clarity – Rhodiola, Bacopa, Galangal, natural caffeine
- Chill – Relaxation & stress relief – Magnolia bark extract, L-theanine
- Go – Physical & mental energy – Caffeine, Plantain, Theobromine, Galangal
- Bliss – Mood elevation & euphoria – Kanna (Sceletium tortuosum), Magnolia
- Love – Arousal & sensory connectedness – Damiana, Muira Puama, Ashwagandha, Catuaba
- Sleep / Midnight – Sleep induction – Herbal sleep aids (reformulated to remove Corydalis/Stephania)
- Boost – Base cannabinoid elevation – single cannabinoid – None (pure cannabinoid carrier)
Mechanism of Action
The pharmacological effect of 1906 Drops relies on a lipid-emulsified micro-encapsulation technology paired with dual-action herbal synergy:
- Fast-Acting Cannabinoid Delivery: Standard cannabis edibles undergo slow hepatic first-pass metabolism where THC is converted in the liver to the more potent hydroxy-THC over 45–120 minutes. 1906 utilizes lipid-based micro-emulsion carriers that facilitate partial transmucosal and rapid upper-gastrointestinal absorption, delivering onset within 15 to 20 minutes.
- Endocannabinoid System (ECS) Activation: THC acts as a partial agonist at receptors (mediating central neurotransmission, mood, and perception) and receptors. CBD acts as a negative allosteric modulator of dampening potential THC-induced anxiety or tachycardia.
- Botanical Multi-Target Synergy: Specific herbal constituents target auxiliary neurochemical pathways:
- L-Theanine & Magnolia: Enhance receptor activity to promote calming effects without heavy sedation.
- Kanna: Contains mesembrine alkaloids that act as natural serotonin reuptake inhibitors (SRIs) and PDE4 inhibitors.
- Rhodiola & Caffeine: Modulate monoamine levels and block adenosine receptors to heighten alertness.
Dosage and Administration
- Standard Dose: 1 tablet (“Drop”) taken orally with water.
- Route: Swallow whole like a conventional pill; do not chew or dissolve under the tongue.
- Onset & Duration: Onset occurs within 15–20 minutes; primary therapeutic duration ranges from 2 to 4 hours.
- Titration: First-time consumers should start with a single low-dose drop (such as Genius or Love at 2.5 mg THC) and wait at least 60 minutes before considering an additional dose.
Side Effects
Common Effects:
- Mild dry mouth (xerostomia) and dry eyes
- Lightheadedness, mild dizziness, or changes in balance
- Mild transient tachycardia (particularly with Go or Genius formulations containing caffeine/stimulants)
- Mild daytime grogginess (with Sleep/Midnight or Chill)
Adverse / Overconsumption Reactions:
- Cannabis-induced acute anxiety, panic, or paranoia (if individual THC sensitivity is high)
- Gastrointestinal upset or nausea
- Excessive sedation or impaired psychomotor skills
Critical Warnings and Safety Concerns
- Hepatotoxicity Risk with Historical Botanical Extracts: State health departments (including Colorado CDPHE) issued advisories regarding previous formulations of Midnight Drops containing Corydalis and Stephania extracts (which contain the isoquinoline alkaloids tetrahydropalmatine [THP] and L-THP). These botanical extracts were linked to acute liver injury and elevated liver enzymes in certain consumers, leading to product recalls and formulation overhauls. Always review product packaging to ensure the formula is free from unverified hepatotoxic botanicals.
- Drug Interactions:
- CYP450 Metabolism: Cannabinoids (CBD and THC) inhibit CYP3A4 and CYP2C19 enzymes, potentially increasing serum concentrations of anticoagulants (e.g., warfarin), antiepileptics, and certain antidepressants.
- Serotonergic Drugs: Formulations containing Kanna (Sceletium tortuosum) or other monoaminergic botanicals carry a theoretical risk of Serotonin Syndrome if combined with prescription SSRIs, SNRIs, or MAOIs.
- CNS Depressants: Co-ingestion with alcohol, benzodiazepines, or opioids multiplies sedative and motor-impairing effects.
- Psychomotor Impairment: Do not drive, operate heavy machinery, or participate in safety-sensitive tasks while under the active influence of any THC-containing product.
- Contraindications: Pregnancy, breastfeeding, or individuals with a personal or family history of psychosis or schizophrenia. Not intended for use by individuals under the legal purchase age (typically 21+).